IN8BIO, Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of gamma-delta T cell therapies for solid and hematological tumors. The company employs allogeneic, autologous, iPSC, and genetically modified approaches to develop cell therapies aimed at identifying and eradicating tumor cells. Its lead product candidates include INB-400, INB-200, and INB-100, which are in various phases of clinical trials for the treatment of glioblastoma and leukemia. IN8BIO utilizes its DeltEx™ platform to harness the therapeutic potential of gamma-delta T cells in cancer treatment.
